PCR analysis of polymorphisms at the D13S25 locus
R E Ibbotson1, R M Chapman, M M Corcoran
1Molecular Biology, Pathology Department, Bournemouth General Hospital, UK.
Leukemia
|November 1, 1996
Summary
Researchers identified a polymorphic marker near a potential tumor suppressor gene linked to B-cell chronic lymphocytic leukemia (B-CLL). PCR amplification of this region significantly improved diagnostic informativity to 80%.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The D13S25 locus is implicated in the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL).
- Loss of heterozygosity (LOH) and bi-allelic loss at this locus suggest the presence of a tumor suppressor gene.
Purpose of the Study:
- To identify and characterize polymorphic markers at the D13S25 locus.
- To enhance the informativity of genetic markers for B-CLL research.
Main Methods:
- Detection of LOH and bi-allelic loss using the pH2-42 probe.
- Sequencing of adjacent clones to identify SspI polymorphism.
- Identification of a polymorphic (TA)n repeat.
- Polymerase Chain Reaction (PCR) amplification of the region containing both markers.
Main Results:
- A novel polymorphic (TA)n repeat was identified adjacent to the SspI polymorphism.
- PCR amplification encompassing both markers increased the informativity of the D13S25 locus to 80%.
Conclusions:
- The identified polymorphic markers provide a more informative tool for investigating the D13S25 locus in B-CLL.
- Enhanced genetic marker informativity aids in understanding the role of tumor suppressor genes in B-CLL pathogenesis.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...